glp-1 drug mounjaro (Tirzepatide): Raising the Bar for Treatments – Nutri-Align World Health Organization issues first-ever
Description
Nutrition Support Whilst on Glucagon-Like Peptide-1 Based Therapy
11 Although not a T2D trial, SELECT (semaglutide) enrolled patients with overweight or obesity (BMI 27 kg/m 2 ) and established CVD
Cuthbertson DJ, Irwin A, Gardner CJ et al (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists
In fact, according to Andels own research, about 44% of members say they would switch jobs for GLP-1 coverage
